APRE Dividend: Aprea Therapeutics Inc Yield Insights

Income

Balance sheet

Cash flow

Annual

Quarterly

APRE Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	0	1	0	0	0	0
Revenue Growth (YoY)	-100%	--	--	--	--	--
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Selling, General & Admin	5	6	8	20	13	14
Research & Development	8	9	7	92	23	37
Operating Expenses	14	15	16	113	37	52
Other Non Operating Income (Expenses)	--	--	--	--	--	--
Pretax Income	-13	-12	-14	-112	-37	-53
Income Tax Expense	--	0	--	--	--	--
Net Income	-13	-12	-14	-112	-37	-53
Net Income Growth	0%	-14%	-88%	202.99%	-30%	89%
Shares Outstanding (Diluted)	6.37	5.5	3.61	1.66	1.06	1.06
Shares Change (YoY)	7%	52%	118%	56.99%	0%	1%
EPS (Diluted)	-2.04	-2.35	-3.94	-67.86	-35.02	-50.45
EPS Growth	-10%	-40%	-94%	94%	-31%	89%
Free Cash Flow	-13	-13	-12	-25	-37	-41
Free Cash Flow Per Share	-2.03	-2.35	-3.31	-15.06	-34.9	-38.67
Gross Margin	--	--	--	--	--	--
Operating Margin	0%	-1,400%	0%	0%	0%	0%
Profit Margin	0%	-1,200%	0%	0%	0%	0%
Free Cash Flow Margin	0%	-1,300%	0%	0%	0%	0%
EBITDA	-13	-14	-15	-113	-37	-52
EBITDA Margin	0%	-1,400%	0%	0%	0%	0%
D&A For EBITDA	0	0	0	0	0	0
EBIT	-13	-14	-15	-113	-37	-52
EBIT Margin	0%	-1,400%	0%	0%	0%	0%
Effective Tax Rate	--	0%	--	--	--	--